Cargando…
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.
Previously we described the clinical aspects of a phase I study of prolonged continuous infusion of low-dose recombinant interleukin-2 (rIL-2). In the present paper we report several immunological effects in 13 patients with melanoma and renal cell cancer treated on an out-patient basis with rIL-2 f...
Autores principales: | Vlasveld, L. T., Hekman, A., Vyth-Dreese, F. A., Rankin, E. M., Scharenberg, J. G., Voordouw, A. C., Sein, J. J., Dellemijn, T. A., Rodenhuis, S., Melief, C. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968412/ https://www.ncbi.nlm.nih.gov/pubmed/8353046 |
Ejemplares similares
-
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.
por: Vlasveld, L. T., et al.
Publicado: (1992) -
Reply to the letter from Janssen et al
por: Vlasveld, L.T., et al.
Publicado: (1994) -
Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma
por: de Gast, G C, et al.
Publicado: (2003) -
Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
por: Verra, N, et al.
Publicado: (2003) -
Immunological Aspects of Chytridiomycosis
por: Grogan, Laura F., et al.
Publicado: (2020)